TY - JOUR
T1 - Treatment of idiopathic pulmonary fibrosis with Nintedanib
T2 - an update
AU - Wongkarnjana, Amornpun
AU - Yanagihara, Toyoshi
AU - Kolb, Martin R.J.
N1 - Funding Information:
M Kolb is a consultant for Prometic, AstraZeneca, NIH, Boehringer-Ingelheim (Review Board). He sits on Advisory Boards for Roche Canada, GSK-Fibrosis Discovery Unit, Australian Pulmonary Fibrosis Research Consortium, Merck and Pulmonary Fibrosis Foundation. He holds grants with Actelion Pharmaceuticals, RespiVert, Sanofi-Aventis, Boehringer-Ingelheim, Patara Pharmaceuticals, and Prometic. T Yanagihara was funded by Mitacs Canada. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/12/2
Y1 - 2019/12/2
N2 - Introduction: Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive and debilitating disease. Nintedanib is one of two anti-fibrotic therapies available for the treatment of IPF and has been approved since 2014. Together with pirfenidone and antacid medications it has received a conditional recommendation for the treatment for IPF by international clinical practice guidelines. Areas covered: The authors review the mechanisms of action, pharmacological profile and update scientific data and our opinions on efficacy, safety profile and tolerability of nintedanib. Expert opinion: Nintedanib significantly slows disease progression in IPF patients with tolerable and manageable side effects. Its potential future role in the treatment of progressive fibrosing interstitial lung diseases other than IPF is challenging.
AB - Introduction: Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive and debilitating disease. Nintedanib is one of two anti-fibrotic therapies available for the treatment of IPF and has been approved since 2014. Together with pirfenidone and antacid medications it has received a conditional recommendation for the treatment for IPF by international clinical practice guidelines. Areas covered: The authors review the mechanisms of action, pharmacological profile and update scientific data and our opinions on efficacy, safety profile and tolerability of nintedanib. Expert opinion: Nintedanib significantly slows disease progression in IPF patients with tolerable and manageable side effects. Its potential future role in the treatment of progressive fibrosing interstitial lung diseases other than IPF is challenging.
UR - http://www.scopus.com/inward/record.url?scp=85074055109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074055109&partnerID=8YFLogxK
U2 - 10.1080/17476348.2019.1673733
DO - 10.1080/17476348.2019.1673733
M3 - Article
C2 - 31564185
AN - SCOPUS:85074055109
SN - 1747-6348
VL - 13
SP - 1139
EP - 1146
JO - Expert Review of Respiratory Medicine
JF - Expert Review of Respiratory Medicine
IS - 12
ER -
